Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025
CLDISAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, is pleased to invite investors to a webinar on November 19, 2025, at 1:15 p.m. PT.
Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
CLDI(CLDI) SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced that its management will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8 to 10, 2025, at the Lotte New York Palace Hotel in New York.
Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
CLDISAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters’ over-allotment option for gross proceeds of $6.9 million, prior to deducting underwriting commissions and offering expenses.
Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering
CLDISAN DIEGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced the pricing of an underwritten public offering for gross proceeds of $6 million prior to deducting underwriting commissions and offering expenses.
Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
CLDISAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today reported its second quarter 2025 operating and financial results and reviewed recent business highlights.
Calidi Biotherapeutics 13G Filing Shows Armistice Capital Reported A 9.99% Stake In The Co As Of March 31, 2025
CLDICalidi Biotherapeutics Q1 EPS $(0.18) Misses $(0.15) Estimate
CLDICalidi Biotherapeutics Says IL15 superagonist Chosen As First Payload To Be Delivered Into Tumors Using Systemic Antitumor Virotherapy Platform, RTNova
CLDICalidi Biotherapeutics Announces The Succession Of Its CEO, Allan Camaisa, To Eric Poma, Who Was Appointed As CEO And Member Of The Board Of Directors, Effective April 22, 2025
CLDICalidi Biotherapeutics Receives FDA Clearance Of IND Application For CLD-201 In Solid Tumors
CLDICalidi Biotherapeutics Q4 EPS (0.27) Down From ($0.23) YoY
CLDICalidi Biotherapeutics Announces Pricing Of $3.9M Registered Direct Offering and Concurrent Private Placement
CLDICalidi Biotherapeutics And City Of Hope Provide Update On Phase 1 Clinical Trial With CLD-101 Virotherapy In Patients With Recurrent High-Grade Glioma; Says 'To date, 14 participants have been treated and all treatment has been well tolerated. The study i
CLDICalidi Biotherapeutics Highlights Delivery Of Transient Gene Therapy (Payload) To Tumors Using Systemic Platform
CLDIWhy Calidi Biotherapeutics (CLDI) Stock Is Down 30%
CLDICalidi Biotherapeutics shares are trading lower by 32% during Friday's session. The company priced its public offering of 5 million shares of common stock at $0.85 per share.
Calidi Biotherapeutics Prices 5M Share Offering At $0.85/Share
CLDICalidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology To Target Metastatic Lung Cancer
CLDICalidi Biotherapeutics Prices $7.5M Public Offering Of 4,437,869 Shares At $1.69/Share
CLDI